1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Optiscan Imaging Limited

Optiscan Imaging Limited

AASX:OIL
0.16
AUD
0.00
(0.00%)
-0.01EPS
125.30MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.01
-0.01
- -
-0.01
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
-0.01
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
0.01
0.01
- -
0.02
0.01
- -
0.02
0.01
0.02
Tangible Book Value per Share
- -
- -
- -
- -
0.01
0.01
- -
0.02
0.01
- -
0.02
0.01
0.02
Basic Weighted Avg Shares
168
199
227
344
426
446
487
587
635
628
829
841
996
Sales/Revenue/Turnover
- -
- -
- -
1
2
1
1
1
1
2
1
1
- -
Operating Margin (%)
-3,196.77
-4,946.91
-776.74
-290.9
-127.5
-252.9
-202.16
-418.47
-539.77
-314.73
-728.18
-984.58
-2,362.67
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Net Income, GAAP
-1
-1
-1
-3
-2
-2
-2
-2
-4
-4
-6
-6
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,972.25
-3,027.42
-431.73
-220.73
-93.13
-225.03
-148.26
-239.08
-417.86
-258.99
-524.44
-663.06
-1,556.71
Working Capital
- -
- -
-1
2
3
3
1
10
6
2
13
7
19
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
1
1
Total Equity
- -
- -
-1
2
3
3
2
10
7
3
14
8
19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-83.64
-77.81
-80.75
-36.15
-50.36
-90.31
-71.67
-58.5
-52.41

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
64.05%
73.49%
145.66%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
25.62%
31.19%
10.68%
Sales/Revenue/Turnover
30.92%
-4.39%
-52.86%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.01
2026
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Camile Farah
Full Time Employees
8
Sector
Health technology
Industry
Medical specialties
Address
16 Miles St Mulgrave VIC Australia 3170
IPO Date
Aug 8, 1997
Website
optiscan.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Optiscan Imaging Limited (ASX: OIL) develops, manufactures and commercializes confocal endomicroscopic imaging technologies that enable real-time, non-destructive, in-vivo digital imaging at the single-cell level for medical, translational, pre-clinical, veterinary and life sciences applications; its core products include InVue, a next-generation microscopic imaging device for precision surgery such as breast cancer procedures; InForm, a digital pathology system for high-resolution cellular imaging at tissue collection without slide preparation; InVivage, an intra-oral endomicroscope for virtual histology in oral cancer detection and dental workflows; ViewnVivo, a flexible endomicroscope for intravital fluorescence confocal imaging in research; and InSpecta, a veterinary point-of-care device for real-time cellular imaging of animal tissues. The Australia-based company, founded in 1994 and headquartered in Mulgrave, Victoria, operates globally with products and collaborations in Australia, the United States, Germany and China, targeting clinicians, pathologists, surgeons, researchers and veterinary professionals in oncology, precision surgery and digital pathology sectors. Recent developments include achieving all milestones in its mid-2024 Know-How Agreement with Mayo Clinic for a robotic-compatible confocal imaging system advancing to the Florida campus in 2025; entering a three-year strategic collaboration with Australian Clinical Labs for InVue and InForm deployment in a first-in-human head and neck cancer study; completing a $17.75 million capital raise led by Peters Investments in FY25; launching telepathology platform MVP and advancing AI imaging with international studies alongside partners like Monash University and UMC Mainz; and maintaining 100% on-time manufacturing with strengthened ISO quality systems.